• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.

机构信息

School of Epidemiology and Public Health, University of Ottawa, Ontario, Canada.

Institute of Health Economics, Alberta, Canada.

出版信息

J Med Econ. 2022 Jan;25(sup1):1-7. doi: 10.1080/13696998.2021.2014721.

DOI:10.1080/13696998.2021.2014721
PMID:35012427
Abstract

Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.

摘要

健康经济评估是对不同行动方案的成本和结果进行的比较分析。2013 年发布的《健康经济评估报告标准(CHEERS)》声明旨在确保健康经济评估具有可识别性、可解释性和对决策有用。其目的是为了帮助作者准确报告正在比较的健康干预措施以及在什么背景下进行比较、评估是如何进行的、发现了什么结果以及其他可能有助于读者和评论员理解和使用研究的详细信息。新的 CHEERS 2022 声明取代了之前的 CHEERS 报告指南。它反映了需要一种更易于应用于所有类型的健康经济评估、该领域的新方法和新进展以及利益相关者(包括患者和公众)参与程度增加的指导。它也广泛适用于任何旨在改善个人或人群健康的干预措施,无论其简单或复杂,且不考虑背景(如医疗保健、公共卫生、教育、社会关怀等)。本文总结了新的 CHEERS 2022 清单,共 28 项,以及对每个项目的建议。CHEERS 2022 声明主要针对为同行评审期刊报告经济评估的研究人员以及评估其发表的同行评审员和编辑。然而,我们预计熟悉报告要求对计划研究的分析师也将是有用的。对于寻求报告指南的医疗技术评估机构来说,它可能也很有用,因为决策的透明度越来越受到重视。

相似文献

1
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
J Med Econ. 2022 Jan;25(sup1):1-7. doi: 10.1080/13696998.2021.2014721.
2
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
BJOG. 2022 Feb;129(3):336-344. doi: 10.1111/1471-0528.17012.
3
Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
Int J Technol Assess Health Care. 2022 Jan 11;38(1):e13. doi: 10.1017/S0266462321001732.
4
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.《2022 年健康经济评估报告标准》(CHEERS 2022)声明:健康经济评估报告的更新指南。
Value Health. 2022 Jan;25(1):3-9. doi: 10.1016/j.jval.2021.11.1351.
5
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
Eur J Health Econ. 2022 Nov;23(8):1309-1317. doi: 10.1007/s10198-021-01426-6. Epub 2022 Jan 27.
6
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.《2022年卫生经济评估报告合并标准》(CHEERS 2022)声明:卫生经济评估的更新报告指南。
Clin Ther. 2022 Feb;44(2):158-168. doi: 10.1016/j.clinthera.2022.01.011. Epub 2022 Feb 12.
7
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
J Manag Care Spec Pharm. 2022 Feb;28(2):146-155. doi: 10.18553/jmcp.2022.28.2.146.
8
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
BMC Health Serv Res. 2022 Jan 27;22(1):114. doi: 10.1186/s12913-021-07460-7.
9
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
BMC Med. 2022 Jan 12;20(1):23. doi: 10.1186/s12916-021-02204-0.
10
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.2022 年健康经济评估报告标准(CHEERS 2022)声明:健康经济评估报告的更新指南。
BMC Public Health. 2022 Jan 27;22(1):179. doi: 10.1186/s12889-021-12491-0.

引用本文的文献

1
Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.利拉鲁肽与度拉鲁肽或口服司美格鲁肽治疗2型糖尿病患者的经济学评价:一项系统评价
Diabetol Metab Syndr. 2025 Aug 27;17(1):358. doi: 10.1186/s13098-025-01927-x.
2
Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services.骨折联络服务中多组分依从性干预的成本效益。
Expert Rev Pharmacoecon Outcomes Res. 2024 Oct;24(8):987-996. doi: 10.1080/14737167.2024.2366439. Epub 2024 Jun 12.
3
Lived experience and family engagement in psychiatry research: A scoping review of reviews.
精神科研究中的生活体验和家庭参与:综述的综述范围界定。
Health Expect. 2024 Jun;27(3):e14057. doi: 10.1111/hex.14057.
4
Costs of endovascular and open repair of thoracic aortic aneurysms.胸主动脉瘤腔内修复与开放修复的成本。
Br J Surg. 2024 Jan 3;111(1). doi: 10.1093/bjs/znad378.
5
Cost-effectiveness analysis of fracture liaison services: a Markov model using Dutch real-world data.骨折联络服务的成本效益分析:使用荷兰真实世界数据的马尔可夫模型。
Osteoporos Int. 2024 Feb;35(2):293-307. doi: 10.1007/s00198-023-06924-2. Epub 2023 Oct 3.
6
The cost-utility of a return-to-work intervention in comparison to routine care for patients with mental disorders in Germany: Results from the RETURN project.德国精神障碍患者重返工作岗位干预措施与常规护理的成本-效用比较:RETURN 项目的结果。
Eur Psychiatry. 2023 Jul 24;66(1):e55. doi: 10.1192/j.eurpsy.2023.2427.
7
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.中国内地绝经后骨质疏松症伴近期骨折患者四种治疗策略的经济性评价:成本效果分析。
Arch Osteoporos. 2023 Jul 17;18(1):100. doi: 10.1007/s11657-023-01309-8.
8
Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.气管内布地奈德联合表面活性剂治疗极早产儿支气管肺发育不良的生存获益:国际多中心随机 PLUSS 试验研究方案。
Trials. 2023 May 9;24(1):320. doi: 10.1186/s13063-023-07257-5.
9
A model-based cost-effectiveness analysis of fracture liaison services in China.基于模型的中国骨折联络服务的成本效果分析。
Arch Osteoporos. 2022 Oct 5;17(1):132. doi: 10.1007/s11657-022-01170-1.